Clene INC Form 4 insider transactions

Clene Inc. Director and 10% owner Chidozie Ugwumba reported multiple sales of common stock totaling 24,770 shares in early 2026.

Clene Inc. Director and 10% owner Chidozie Ugwumba sold 19,274 shares of common stock totaling approximately $96,040 over three days in late January 2026, pursuant to a Rule 10b5-1 plan.

A director and 10% owner of Clene Inc. has sold over $96,000 worth of common stock in two separate transactions.

Clene Inc.'s Chief Financial Officer, Morgan R. Brown, was granted 35,000 stock options with an exercise price of $5.42 per share, vesting immediately.

Clene Inc.'s Chief Science Officer, Mark Mortenson, was granted 75,000 stock options at an exercise price of $5.42 per share, vesting immediately.

Clene Inc.'s President and CEO, Robert Dee Etherington, was granted 75,000 stock options at an exercise price of $5.42 per share, vesting immediately.

Clene Inc. Director and 10% owner Chidozie Ugwumba reported sales of common stock totaling 32,474 shares through Symbiosis II, LLC.

Chidozie Ugwumba, a director and 10% owner of Clene Inc., sold 58,289 shares of common stock over three separate transactions in mid-January 2026.

Clene Inc. Director Alison Mosca, through an affiliated LLC, acquired additional common stock and warrants, signaling increased insider confidence.

Clene Inc. Director and 10% owner David J. Matlin acquired 33,333 shares of common stock and associated warrants at $6.50 per unit, signaling increased insider confidence.

Clene Inc. Director and 10% owner Chidozie Ugwumba, through Symbiosis II, LLC, sold a total of 44,975 shares of common stock for approximately $280,000 in early January 2026.

Clene Inc. Director and 10% owner, Chidozie Ugwumba, reported selling a total of 12,918 shares of common stock over three days in early January 2026.

Clene Inc. Director and 10% owner Chidozie Ugwumba reported sales of common stock totaling 17,110 shares across two transactions in late 2025 and early 2026, executed under a Rule 10b5-1 plan.

Clene Inc. Director and 10% owner Chidozie Ugwumba reported sales of common stock totaling 12,234 shares through an indirect holding.

A Clene Inc. director and 10% owner exercised pre-funded warrants and subsequently sold a portion of the acquired common stock.

Ugwumba Chidozie, a Director and 10% Owner of Clene Inc., reported planned sales of common stock totaling 9,949 shares in December 2025.

Clene Inc. Director and 10% owner Chidozie Ugwumba, through Symbiosis II, LLC, disposed of 257,795 shares of common stock over multiple transactions in December 2025.

Clene Inc. Director Matthew Kiernan was granted 1,893 stock options with an exercise price of $7.30 per share, vesting immediately.

Clene Inc. Director Jonathon Gay was granted 2,438 stock options at an exercise price of $7.30 per share, vesting immediately.

Clene Inc. Director Alison Mosca was granted 2,887 stock options with an exercise price of $7.30 per share, vesting immediately.

Clene Inc. Director Shalom Jacobovitz was granted 2,816 stock options at an exercise price of $7.30 per share, vesting immediately.

Clene Inc. Director David J. Matlin was granted 3,692 stock options under the company's 2020 Stock Plan, vesting immediately.

Clene Inc. Director Arjun JJ Desai was granted 2,177 stock options, vesting immediately, at an exercise price of $7.30 per share under the company's 2020 Stock Plan.

Clene Inc. Director Vallerie McLaughlin was granted 2,083 stock options at an exercise price of $7.30 per share, vesting immediately.

Clene Inc. Director Reed Wilcox received a grant of 1,893 stock options with an exercise price of $7.30 per share, vesting immediately.

Clene Inc.'s Chief Science Officer, Mark Mortenson, filed an amended Form 4 to correct the exercise price of 40,000 stock options to $5.88 per share.

An amended SEC Form 4 clarifies the exercise price for CEO Robert Etherington's 40,000 stock options to $5.88 per share.

Clene Inc.'s Chief Financial Officer, Morgan R. Brown, filed an amended Form 4 to correct the exercise price of a previously reported stock option.

Clene Inc.'s Chief Science Officer, Mark Mortenson, was granted 40,000 stock options at an exercise price of $6.05 per share, vesting monthly over one year.

Clene Inc.'s President and CEO, Robert Dee Etherington, was granted 40,000 stock options at an exercise price of $6.05 per share, vesting monthly over one year.